This is a case-based activity that includes discussion of a 43-year old female with newly diagnosed Chronic Lymphocytic Leukemia (CLL), diagnosed in 2012, initially managed with observation. In February 2014, the patient comes for a follow-up with no symptoms. The patient completes six cycles of FCR and enters a complete remission, albeit MRD positive. She is serially observed, and two years later returns to clinic with the following lab results:WBC 25, HgB 11, Platelets 110,000. This case presentation engages users to consider best next steps as the faculty lead in discussion.
At the end of this course you should be able to:
- Assess the efficacy and toxicity of novel small molecule inhibitors for Chronic Lymphocytic Leukemia.
- Evaluate advantages of chemo-immunotherapy in front line therapy of selected patients with low risk CLL
- Review the role of specific CLL –related risk factors for choice of appropriate CLL therapy in the front-line setting
This activity was made available on 5/20/2015 and will be reviewed on an annual basis to determine continued availability. A maximum of 1 AMA PRA Category 1 Credit(s) ™ credit is available.
Medical Knowledge (ACGME, AAPA)
Health Promotion, Health Protection, Disease Prevention, and Treatment (ONS)
Note: This course is now accessible through mobile devices as well as personal computers